Found 77 matching trials
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. PHASE2 This study is a multicenter, prospective, randomized, double-arm, Phase II ...
Show More Location
Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651
Learn More & Join Trial
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. PHASE3 The trial aimed to compare QL1706 combined with induction chemotherapy plus...
Show More Location
Fujian Cancer Hospital
Learn More & Join Trial
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma PHASE2 This is single - arm study to explore the safety and efficacy of iparomlima...
Show More Location
The First Affiliated Hospital of Zhengzhou University
Learn More & Join Trial
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer PHASE2 This study is a prospective, single-arm, multicenter exploratory clinical s...
Show More Location
Jiangsu Cancer Hospital
Learn More & Join Trial
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer PHASE2 This study will enroll patients with locally advanced non-small cell lung c...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) PHASE2 Locally advanced cervical cancer (LACC) remains a significant global health...
Show More Location
Fujian Cancer Hospital
Learn More & Join Trial
Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC PHASE2 This is a two-arm, randomized, multicenter phase II clinical study to evalu...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT PHASE2 The goal of this prospective, single-arm, multi-center Phase II clinical tr...
Show More Location
Nanfang Hospital of Southern Medical University
Learn More & Join Trial
Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer PHASE2 The study aims to evaluate the efficacy and safety of the QL1706 combinatio...
Show More Location
Multiple Locations
Learn More & Join Trial
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus PHASE2 The purpose of this study is to learn how well a combination of iparomlimab...
Show More Location
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Learn More & Join Trial